Renaissance Capital logo

Caribou Biosciences Priced, Nasdaq: CRBU

Phase 1 biotech developing gene edited cell therapies for multiple cancers.

Industry: Health Care

Latest Trade: $1.87 0.00 (0.0%)

First Day Return: +2.0%

Return from IPO: -88.3%

Industry: Health Care

We are a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying our novel CRISPR platform, CRISPR hybrid RNA-DNA, or chRDNA, pronounced “chardonnay,” toward the development of next-generation, genome-edited cell therapies. Our renowned founders, including a Nobel laureate, are pioneers in CRISPR genome editing. Our chRDNA technology has demonstrated superior specificity and high efficiency in preclinical studies, which enables us to perform multiple, precise genomic edits, while maintaining genomic integrity. We believe that our technology has broad potential to generate gene and cell therapies in oncology and in therapeutic areas beyond oncology, including immune cell therapies, cell therapies derived from genome-edited iPSCs, and in vivo genome-editing therapies. The genome-editing technologies currently used in the allogeneic cell therapy field generally have limited efficiency, specificity, and versatility for performing the multiple, precise genomic edits necessary to address insufficient persistence. Our chRDNA technology is designed to address these genome-editing limitations and improve cell therapy activity. By applying this approach to allogeneic cell therapies, we believe we can unlock their full potential by improving upon their effectiveness and durability.
more less
IPO Data
IPO File Date 07/01/2021
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 19.0
Deal Size ($mm) $304
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 07/22/2021
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 19.0
Deal Size ($mm) $304
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
BofA Securities
Citi
more
Company Data
Headquarters Berkeley, CA, United States
Founded 2011
Employees at IPO 67
Website www.cariboubio.com

Caribou Biosciences (CRBU) Performance